External quality assessment of genetic testing for Glucose-6-phosphate dehydrogenase deficiency in Shanghai and other regions
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most prevalent enzymatic disorder of red blood cells. Early identification of at‑risk individuals through genetic testing facilitates the implementation of targeted preventive measures to reduce disease burden. However, the accuracy and reliability of molecular testing across clinical laboratories have not been systematically established. This pioneering study assessed current laboratory performance in analyzing and reporting G6PD-related variants through an annual external quality assessment (EQA) program. A panel of five dried blood spots (DBS) mimicking samples was prepared from distinct cell lines and distributed to participants. The sample panel contained four positive samples carrying G6PD pathogenic variants, including hemizygous, heterozygous, and compound heterozygous genotypes, and one negative sample. Of 23 participating laboratories, only 14 (60.87%) achieved full marks. Although all participants successfully detected pathogenic mutations, 49 variant reporting errors were identified and categorized into four types. Most laboratories yielded satisfactory results; however, improvements are needed in variant description and result reporting. These findings highlight the necessity of continued education on international reporting standards and robust quality assurance to ensure accurate, consistent genetic variants interpretation across laboratories.
Authors
- Pengyin Zhang
- Jing Quan (ORCID: https://orcid.org/0000-0002-7850-4511)
- Yun Bao (ORCID: https://orcid.org/0009-0009-1459-0172)
- Xiaobo Hu
- Xue Yang
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1371/journal.pone.0362593
- Primary Topic
- Neonatal Health and Biochemistry
- Type
- article
- Field-Weighted Citation Impact
- 0.00